[Comment] Genomic profiling and diagnostic biomarkers in Alzheimer's disease

Biomarkers will be essential in identifying individuals with prodromal Alzheimer's disease and stratifying participants in clinical trials. In a Policy View in The Lancet Neurology, Giovanni Frisoni and colleagues1 set out the evidence on Alzheimer's disease diagnostic biomarkers, using a framework previously developed in oncology. Their comprehensive review of neuroimaging and CSF biomarkers draws attention to the lack of common standards and clinical validation across health systems, and the subsequent effects on diagnosis.
Source: Lancet Neurology - Category: Neurology Authors: Tags: Comment Source Type: research